/PTN

PTN Stock - Palatin Technologies, Inc.

Q: What is the analyst price target for PTN?

Analyst price target information is not currently available for PTN.

Q: What is PTN's market cap?

Market capitalization information is not currently available for PTN.

Healthcare|Biotechnology|AMEX

$17.05-10.69%

$2.04 (-10.69%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+222.6%upside

Target: $55.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PTN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.94

52W High$72.50

52W Low$2.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	$4.49M	$4.85M	$1.47M	$-188,597
Gross Profit	$-258,917	$4.39M	$4.44M	$1.25M	$-336,437
Gross Margin	N/A	97.8%	91.4%	85.2%	178.4%
Operating Income	$-22,707,839	$-22,496,121	$-32,458,883	$-36,588,448	$-33,384,101
Net Income	$-17,307,349	$-29,736,113	$-24,036,741	$-36,198,299	$-33,568,814
Net Margin	N/A	-662.3%	-495.2%	-2465.1%	17799.2%
EPS	$-32.15	$-2.02	$-2.21	$-3.79	$-3.55

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

$55

Average Target

↑ 222.6% Upside

Now

$50

Low

$55

Average

$60

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 12th 2025	Laidlaw	Initiation	Buy	$60
December 3rd 2025	Alliance Global Partners	Initiation	Buy	$50

Earnings History & Surprises

PTN

Beat Rate

50%

Last 18 quarters

Avg Surprise

-6.7%

EPS vs Estimate

Beats / Misses

9/7

2 met exactly

Latest EPS

$4.26

Q4 2025

EPS Surprise History

Q1 24

-30.2%

$-0.56vs$-0.43

Q2 24

+19.7%

$-0.53vs$-0.66

Q3 24

+12.5%

$-0.49vs$-0.56

Q4 24

+7.3%

$-0.51vs$-0.55

Q1 25

+71.4%

$-0.12vs$-0.42

Q2 25

-211.8%

$-0.53vs$-0.17

Q3 25

+56.4%

$-4.14vs$-9.50

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 12, 2026	—	—	—	—
Q4 2025	Nov 14, 2025	—	$4.26	—	—
Q3 2025	Sep 23, 2025	$-9.50	$-4.14	+56.4%	✓ BEAT
Q2 2025	May 21, 2025	$-0.17	$-0.53	-211.8%	✗ MISS
Q1 2025	Feb 13, 2025	$-0.42	$-0.12	+71.4%	✓ BEAT
Q4 2024	Oct 1, 2024	$-0.55	$-0.51	+7.3%	✓ BEAT
Q3 2024	Sep 30, 2024	$-0.56	$-0.49	+12.5%	✓ BEAT
Q2 2024	May 15, 2024	$-0.66	$-0.53	+19.7%	✓ BEAT
Q1 2024	Feb 14, 2024	$-0.43	$-0.56	-30.2%	✗ MISS
Q4 2023	Nov 14, 2023	$-0.75	$-0.48	+36.0%	✓ BEAT
Q3 2023	Sep 28, 2023	$-0.59	$-0.91	-54.2%	✗ MISS
Q2 2023	May 16, 2023	$-0.59	$-0.63	-6.8%	✗ MISS
Q1 2023	Feb 14, 2023	$-0.77	$-0.66	+14.3%	✓ BEAT
Q4 2022	Nov 14, 2022	$-1.34	$-0.86	+35.8%	✓ BEAT
Q3 2022	Sep 22, 2022	$-0.97	$-1.34	-38.1%	✗ MISS
Q2 2022	May 17, 2022	$-0.75	$-0.75	0.0%	= MET
Q1 2022	Feb 14, 2022	$-0.75	$-1.00	-33.3%	✗ MISS
Q4 2021	Nov 15, 2021	$-0.75	$-0.75	0.0%	= MET
Q3 2021	Sep 29, 2021	$-1.00	$-1.50	-50.0%	✗ MISS
Q2 2021	May 17, 2021	$-1.00	$-0.50	+50.0%	✓ BEAT

Frequently Asked Questions about PTN

What is PTN's current stock price?

Palatin Technologies, Inc. (PTN) is currently trading at $17.05 per share. The stock has moved -10.69% today.

What is the analyst price target for PTN?

The average analyst price target for PTN is $55.00, based on 1 analyst.

What sector is Palatin Technologies, Inc. in?

Palatin Technologies, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.

What is PTN's market cap?

Palatin Technologies, Inc. has a market capitalization of $0.44 billion, making it a small-cap company.

Does PTN pay dividends?

No, Palatin Technologies, Inc. does not currently pay a dividend to shareholders.